Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reconstitution of HIV-specific Immunity Against HIV
NCT02563509Phase 1Completed
- Sponsor
- Guangzhou Eighth People's Hospital
- Start
- Jan 2016
- Primary completion
- Jun 2017
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of HIV-specific cytotoxic T lymphocytes in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Guangzhou Eighth People's Hospital. Primary endpoint: Number and function of HIV-specific CD8 cells at 6 months. Started Jan 2016; status: completed.
02
Drugs
HIV-specific cytotoxic T lymphocytes
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02563509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563509.